Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,

Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: <u>www.sunpharma.com</u> CIN: L24230GJ1993PLC019050



July 31, 2021

National Stock Exchange of India Ltd.,

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051.

NSE Code: SUNPHARMA

BSE Limited,

Market Operations Dept.

P. J. Towers, Dalal Street,

Mumbai - 400 001. **Stock Code: 524715**

Dear Sirs,

<u>Subject:</u> Disclosure under Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015, as amended ("Listing Regulations") read with Securities and Exchange Board of India circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015 ("SEBI Circular").

We refer to our disclosure, dated 31st March 2021, under Regulation 30 of the Listing Regulations informing inter alia that DigiHealth Technologies LLP ("**Digihealth**") [(the wholly owned entity of our investee entity, ABCD Technologies LLP wherein our company holds presently 6.45% share of profit/ loss and voting rights)] had acquired 66.02% ownership interest in AIOCD Pharmasofttech Awacs Private Limited ("**AWACS**") and the acquisition was completed on 30th of March 2021, through a combination of (i) direct purchase of 50% ownership interest in AWACS and (ii) indirect purchase of 16.02% ownership interest in AWACS through acquisition of 32.04% shareholding interest in Trikaal Mediinfotech Private Limited ("**Trikaal**"). Further, it was informed that Digihealth had agreed to acquire the remaining 33.98% ownership interest in AWACS and had entered into legally binding agreements for such acquisition of the remaining stake.

Further to the above and in terms of Regulation 30 of Listing Regulations read with SEBI Circular, we wish to inform you that Digihealth has now completed, the acquisition of an additional 65.91% of shareholding in Trikaal by purchase of shares from certain shareholders of Trikaal at a cash consideration of Rs. 24,71,52,845 (Indian Rupees Twenty-Four Crores Seventy One Lakh Fifty Two Thousand Eight Hundred and Forty Five only) and thereby indirectly, Digihealth has completed the acquisition of a total of 98.97 % of shareholding in AWACS.

In furtherance, we would also wish to inform you that the acquisition of remaining shareholding of 2.05% in Trikaal is envisaged to be completed over the course of next few months subject to

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,

Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: <u>www.sunpharma.com</u> CIN: L24230GJ1993PLC019050



certain terms and conditions.

We request you to kindly take this in your record and disseminate.

Thanking you,
Yours faithfully,
For Sun Pharmaceutical Industries Limited

Ashok Bhuta Sr. GM – Secretarial & Compliance Officer

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.